Previous 10 | Next 10 |
2023-06-23 11:12:16 ET As Wall Street approaches the midpoint of 2023, many mid-cap stocks have provided investors with sizable returns. Of the roughly 1,000 mid-cap stocks available for investors, 101 of them have returned 50% or more since the end of 2022. This includes several ralli...
2023-06-20 18:49:40 ET Summary A Prior Approval Supplement for Reata Pharmaceuticals, Inc.'s SKYCLARYS for Friedreich's Ataxia has been submitted with a Priority Review Date of Mid-August 2023. It is expected that the global Friedreich's Ataxia market could reach $2.06 billion by ...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announ...
2023-06-15 11:57:12 ET Reata Pharmaceuticals ( NASDAQ: RETA ) shed ~13% in the morning hours Thursday after the company's chief financial officer and chief operating officer Manmeet Soni sold millions of dollars worth of its shares early this week. According to a regula...
2023-06-15 10:06:53 ET Gainers: Aldeyra Therapeutics ( ALDX ) +11% . Bioventus ( BVS ) +11% . IO Biotech ( IOBT ) +11% . Verastem ( VSTM ) +10% . Zentalis Pharmaceuticals ( ZNTL ) +9% . Losers: Mersana Therapeutics ( MRSN...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announ...
2023-06-12 14:00:28 ET SVB upgrades Reata Pharmaceuticals ( NASDAQ: RETA ) to 'Outperform' from 'Market Perform', increases PT to $115 from $80 Brokerage believes the company's manufacturing issues will be fixed in the near term, thus erasing the only roadblock to...
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announ...
2023-05-24 14:26:51 ET Shares of Reata Pharmaceuticals ( NASDAQ: RETA ) and PTC Therapeutics ( PTCT ) moved in opposite directions on Wednesday after the latter faced a setback for vatiquinone, a Phase 3 candidate for the neuromuscular disorder Friedreich's ataxia (FA). Whil...
2023-05-24 08:28:00 ET EpicQuest Education Group International ( EEIQ ) +92% . GigaCloud Technology ( GCT ) +37% Q1 earnings call release The Necessity Retail ( RTL ) +25% necessity retail rEIT to merge and internalize management. Smart for ...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...